...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of experimental & clinical cancer research : >The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
【24h】

The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)

机译：个性化医学和免疫肿瘤学时代临床试验的不断变化：国际肿瘤学和血液肿瘤学国际临床大会报告（ICTO 2017）

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the past decade, the oncology community has witnessed major advances in the understanding of cancer biology and major breakthroughs in several different therapeutic areas, from solid tumors to hematological malignancies; moreover, the advent of effective immunotherapy approaches, such as immune-checkpoint blockade, is revolutionizing treatment algorithms in almost all oncology disease areas. As knowledge evolves and new weapons emerge in the “war against cancer”, clinical and translational research need to adapt to a rapidly changing environment to effectively translate novel concepts into sustainable and accessible therapeutic options for cancer patients. With this in mind, translational cancer researchers, oncology professionals, treatment experts, CRO and industry leaders, as well as patient representatives gathered in London, 16-17 March 2017, for The International Congress on Clinical Trials in Oncology and Hemato-Oncology (ICTO2017), to discuss the changing face of oncology clinical trials in the new era of personalized medicine and immuno-oncology. A wide range of topics, including clinical trial design in immuno-oncology, biomarker-oriented drug development paths, statistical design and endpoint selection, challenges in the design and conduct of personalized medicine clinical trials, risk-based monitoring, financing and reimbursement, as well as best operational practices, were discussed in an open, highly interactive format, favoring networking among all relevant stakeholders. The most relevant data, approaches and issues emerged and discussed during the conference are summarized in this report.
机译：在过去的十年中，肿瘤学界见证了对癌症生物学认识的重大进步，以及从实体瘤到血液系统恶性肿瘤等多个不同治疗领域的重大突破。此外，有效的免疫治疗方法的出现，例如免疫检查点封锁，正在彻底改变几乎所有肿瘤疾病领域的治疗算法。随着知识的发展和“抗癌战争”中新武器的出现，临床和转化研究需要适应迅速变化的环境，以有效地将新概念转化为癌症患者的可持续和可及的治疗选择。考虑到这一点，转化癌症研究人员，肿瘤学专业人士，治疗专家，CRO和行业领导者以及患者代表于2017年3月16日至17日聚集在伦敦，参加了国际肿瘤学和血液肿瘤临床试验国际会议（ICTO2017） ），讨论个性化医学和免疫肿瘤学新时代肿瘤学临床试验不断变化的面貌。广泛的主题，包括免疫肿瘤学的临床试验设计，面向生物标志物的药物开发途径，统计设计和终点选择，个性化药物临床试验的设计和进行中的挑战，基于风险的监测，融资和报销，以开放，高度互动的形式讨论了最佳操作实践，并促进了所有相关利益相关方之间的联网。报告总结了会议期间出现和讨论的最相关的数据，方法和问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号